Form 4: Regulus Therapeutics Director, David Baltimore, Receives Stock Awards

Director David Baltimore received 62,500 Restricted Stock Units from Regulus Therapeutics, vesting monthly over 12 months.

Summary

• David Baltimore, a director at Regulus Therapeutics Inc., received 62,500 Restricted Stock Units on April 30, 2025.
• These units vest in equal monthly installments over a 12-month period from the grant date.
• Following the transaction, Mr. Baltimore directly owns 84,669 shares of common stock.
• Mr. Baltimore's spouse also owns 62,500 shares of common stock indirectly.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a common practice and generally viewed as a positive sign of alignment between management and shareholders.

Positives

• The grant of Restricted Stock Units to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company over the next year.

Future Outlook

The vesting of the Restricted Stock Units over the next 12 months suggests an expectation of continued service and contribution from the director.

Industry Context

Stock awards are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders and incentivizing long-term value creation.

Stakeholder Impact

• The stock award aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.
• The vesting schedule incentivizes the director to remain with the company and contribute to its success.

Key Dates

Keywords

Regulus Therapeutics, RGLS, David Baltimore, Director, Restricted Stock Units, Stock Award, Beneficial Ownership, Form 4